Maki Yamamoto, MD

Dr. Lauren C. Pinter-Brown is a board-certified, fellowship-trained UCI hematologist-oncologist who specializes in the diagnosis and treatment of patients with lymphomas. A nationally recognized expert, Pinter-Brown has a longstanding interest in malignant lymphoma, with a particular focus on T-cell and skin lymphomas. Her clinical interests also include antiphospholipid, B-cell lymphoma, Hodgkin's lymphoma, mycosis fungoides, non-Hodgkins lymphoma, stem-cell transplant and Waldenstrom's disease. She her medical degree at the David Geffen School of Medicine at UCLA Medical School, followed by an internship and residency in internal medicine at Harbor-UCLA Medical Center. She completed a fellowship in hematology and oncology at the Keck School of Medicine at USC. A prolific clinical investigator, Pinter-Brown has made important contributions to several clinical trials that led to approval of new drugs for the treatment of T-cell lymphoma. Her research focus is on optimizing treatment options for patients with lymphoma, especially cutaneous and T-cell lymphomas. Her primary goal is to care for patients through diagnosis, treatment and beyond and to ensure that they are able "to live their best life." Pinter-Brown, who speaks Spanish.

Dr. Richard Van Etten is a board-certified, fellowship-trained UCI Health hematologist and oncologist who specializes in the treatment of leukemia and other blood cancers. His clinical focus also includes hematopoetic stem cell transplant services. He is the director of the Chao Family Comprehensive Cancer Center, where he leads a team of more than 250 physicians, basic and translational scientists conducting cancer research at UC Irvine.Van Etten received a medical degree and a PhD in biophysics from the Stanford University School of Medicine, where he worked with biochemist David F. Clayton, PhD, on the molecular genetics of mammalian mitochondrial DNA and brain development. He went on to complete a residency in internal medicine and a fellowship in hematology at Harvard School of Medicine and Brigham & Women's Hospital in Boston. Next he worked as a visiting scientist in the lab of Nobel laureate David Baltimore at the Massachusetts Institute of Technology's Whitehead Institute in Boston.He joined the Harvard Medical School and Brigham & Women's Hospital as a faculty member of the departments of Medicine and Genetics. In 2003, he became a professor of Medicine at Tufts Medical Center and director of the Hematologic Malignancies Program at Tufts Cancer Center, eventually becoming chief of the Division of Hematology/Oncology. In 2009, he was named director of the Tufts Cancer Center.Van Etten became director of the Chao Family Comprehensive Cancer Center on Oct. 1, 2013 and a professor of Medicine and Biochemistry in the UCI School of Medicine. Under his leadership, the cancer center's comprehensive cancer center designation has been renewed twice by the National Cancer Institute. He is the author of more than 150 scientific articles, reviews and book chapters. His research lab, which is funded by grants from the National Cancer Institute, investigates the molecular pathogenesis of leukemia and myeloproliferative neoplasms with an emphasis on dysregulated tyrosine kinases and mouse model systems.

Dr. Mo Ziari is a board-certified UCI Health hematologist and medical oncologist who specializes in the diagnosis, treatment and management of solid tumors as well as benign and malignant hematological conditions. He earned his medical degree at Shiraz University of Medical Sciences in Shiraz, Iran. Next, he completed a residency in internal medicine at Saint Louis University School of Medicine in Saint Louis, Mo., followed by fellowship training in hematology and oncology at the University of Texas Southwestern in Dallas. Ziari delivers leading-edge cancer therapies, including chemotherapy, endocrine therapy, targeted therapy, monoclonal antibodies and immunotherapy. He is the author of numerous peer-reviewed journal articles. He sees patients in Costa Mesa and Orange.